Paul A. Stone - 21 Aug 2023 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Signature
/s/ Jason Throne, as Attorney-in-Fact for Paul A. Stone
Issuer symbol
IDYA
Transactions as of
21 Aug 2023
Net transactions value
-$25,819
Form type
4
Filing time
23 Aug 2023, 18:31:54 UTC
Previous filing
18 Aug 2023
Next filing
31 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Sale $25,819 -978 -6.4% $26.40 14,303 21 Aug 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $26.38 to $26.4175, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.